Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Apr;7(4):495-503.
doi: 10.1517/17425255.2011.565331. Epub 2011 Mar 20.

Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation

Affiliations
Review

Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation

Jean-Jacques Parienti et al. Expert Opin Drug Metab Toxicol. 2011 Apr.

Erratum in

  • Expert Opin Drug Metab Toxicol. 2011 Jun;7(6):783

Abstract

Introduction: Nevirapine (NVP), a non-nucleoside reverse transcriptase inhibitor, has been an important component of HIV infection treatment for many years. Currently, twice-a-day dosing is required for the successful application of NVP immediate release (IR), but there is potential for a more convenient once-a-day antiretroviral combination.

Areas covered: The purpose of this article is to review the recent data on once-daily NVP extended release (XR) looking at all the important pharmacologic, pharmacokinetic and clinical data on NVP IR/XR through a systematic MEDLINE database search as well as a review of abstracts presented at international HIV meetings on NVP XR studies up to December 2010. The article provides the reader with an overview of all the pharmacodynamic and pharmacokinetic aspects of NVP IR/XR, as well as its preclinical and clinical efficacy and its safety.

Expert opinion: NVP XR is as effective as NVP IR among HIV-infected patients with a similar safety profile. NVP XR requires careful monitoring during initiation, but its favorable lipid profile may be of clinical benefit in reducing the risk for coronary artery disease in HIV-infected patients who are receiving long-term antiretroviral therapy. Further research is needed to predict short-term toxicity.

PubMed Disclaimer

Similar articles

Cited by

MeSH terms

LinkOut - more resources